Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

AKATSUKI 48-Week Interim Analysis: Emicizumab and Immune Tolerance Induction in People with Hemophilia A and Factor VIII Inhibitors

Tadashi Matsushita, Nobuaki Suzuki, Chiai Nagae, Azusa Nagao, Masahiko Ando, Yachiyo Kuwatsuka, Daisuke Nosaka, Yui Kyogoku, Tomomi Shimura, Keiji Nogami

Blood (2023) 142 (Supplement 1): 2625.

https://doi.org/10.1182/blood-2023-173071

Published: 2023

Journal Articles

Efficacy and Safety of Emicizumab Prophylaxis in Patients with Acquired Hemophilia a Who Were Deemed Ineligible for Immunosuppressive Therapy: Additional Data from the Ageha Study

Hidekazu Nishikii, Nobuaki Suzuki, Ryota Kobayashi, Narumi Mizuno, Ryoto Ozaki, Midori Shima

Blood (2022) 140 (Supplement 1): 2724–2725.

https://doi.org/10.1182/blood-2022-162237

Published: 2022

Journal Articles

Genetic Analysis of Von Willebrand Disease By Using the Exome Sequencing Approach

Naomi Sanda, Msc, Nobuaki Suzuki, MD PhD, Takeshi Kanematsu, MD, Mika Ogawa, MD, Mayuko Kishimoto, MD PhD, Shigeo Nakamura, MD PhD, Tadashi Matsushita, MD PhD

Blood (2015) 126 (23): 1097.

https://doi.org/10.1182/blood.V126.23.1097.1097

Published: 2015

Journal Articles

Clinical Course and Management of Surgical Emergency in a Severe Hemophilia a Patient Under Weekly Subcutaneous Administration of a Bispecific Antibody to Factors IXa and X (ACE910)

Takeshi Kanematsu, MD, Nobuaki Suzuki, MD PhD, Naomi Sanda, MSc, Mika Ogawa, MD, Mayuko Kishimoto, MD PhD, Atsuo Suzuki, PhD, Hitoshi Kiyoi, MD PhD, Ryu Kasai, MSc, Tadashi Matsushita, MD PhD

Blood (2015) 126 (23): 1099.

https://doi.org/10.1182/blood.V126.23.1099.1099

Published: 2015

Journal Articles

Establishment of Blood Outgrowth Endothelial Cells from a Type 3 Von Willebrand Disease (VWD) Patient with a Neutralizing Anti-VWF Inhibitors

Naomi Sanda, MSc, Nobuaki Suzuki, MD PhD, Mayuko Kishimoto, MD, Natsumi Kameyama, Yoko Kajiura, Hiroyuki Matsumoto, Shigeo Nakamura, MD PhD, Tadashi Matsushita, MD PhD

Blood (2014) 124 (21): 1508.

https://doi.org/10.1182/blood.V124.21.1508.1508

Published: 2014

Journal Articles

R702C Mutation of the MYH9 Gene Provokes Impaired Platelet Formation, Renal Focal Segmental Glomerulosclerosis, and Hearing Disability In the Mice Model

Nobuaki Suzuki, Shinji Kunishima, PhD, Makoto Ikejiri, Shoichi Maruyama, MD, PhD, Michihiko Sone, MD, PhD, Akira Takagi, Kanji Hirashima, Masahito Ikawa, Masaru Okabe, Tetsuhito Kojima, MD, PhD, Hidehiko Saito, MD, Tomoki Naoe, MD, PhD, Tadashi Matsushita, MD, PhD

Blood (2010) 116 (21): 482.

https://doi.org/10.1182/blood.V116.21.482.482

Published: 2010

NARROW

AKATSUKI 48-Week Interim Analysis: Emicizumab and Immune Tolerance Induction in People with Hemophilia A and Factor VIII Inhibitors

Efficacy and Safety of Emicizumab Prophylaxis in Patients with Acquired Hemophilia a Who Were Deemed Ineligible for Immunosuppressive Therapy: Additional Data from the Ageha Study

Genetic Analysis of Von Willebrand Disease By Using the Exome Sequencing Approach

Clinical Course and Management of Surgical Emergency in a Severe Hemophilia a Patient Under Weekly Subcutaneous Administration of a Bispecific Antibody to Factors IXa and X (ACE910)

Establishment of Blood Outgrowth Endothelial Cells from a Type 3 Von Willebrand Disease (VWD) Patient with a Neutralizing Anti-VWF Inhibitors

R702C Mutation of the MYH9 Gene Provokes Impaired Platelet Formation, Renal Focal Segmental Glomerulosclerosis, and Hearing Disability In the Mice Model

Email alerts

ASH Publications

American Society of Hematology

AKATSUKI 48-Week Interim Analysis: Emicizumab and Immune Tolerance Induction in People with Hemophilia A and Factor VIII Inhibitors

Efficacy and Safety of Emicizumab Prophylaxis in Patients with Acquired Hemophilia a Who Were Deemed Ineligible for Immunosuppressive Therapy: Additional Data from the Ageha Study

Genetic Analysis of Von Willebrand Disease By Using the Exome Sequencing Approach

Clinical Course and Management of Surgical Emergency in a Severe Hemophilia a Patient Under Weekly Subcutaneous Administration of a Bispecific Antibody to Factors IXa and X (ACE910)

Establishment of Blood Outgrowth Endothelial Cells from a Type 3 Von Willebrand Disease (VWD) Patient with a Neutralizing Anti-VWF Inhibitors

R702C Mutation of the MYH9 Gene Provokes Impaired Platelet Formation, Renal Focal Segmental Glomerulosclerosis, and Hearing Disability In the Mice Model

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only